What Happened?
Seattle, WA-based M3 Biotechnology Appointed Leen Kawas as Chief Executive Officer
About the Company
M3 is a biopharmaceutical company focused on development of therapeutics to address Alzheimer`s, Parkinson`s and Neurodegeneration.
About the Person
Dr. Kawas, co-inventor and the CEO of M3 biotechnology Inc. In her scientific role, she is involved in the development of novel therapeutics that target HGF and has directed several aspects of relevant research funded by grants from the National Institute of Health (NIH), Alzheimer`s Drug Discovery and Michael J Fox Foundations. Her research was instrumental in the early development of MM-201 as a neurodegenerative disease drug candidate and thus set the scientific foundation for the development of M3 Biotechnology. Perhaps more significant, her work resulted in the discovery of a novel approach to drug design that yields allosteric regulators of large-growth-factor proteins. This background gives her a unique appreciation for the interplay between the chemistry and biology that underlies M3`s platform. Also, her unique scientific and medical knowledge give her the credibility to lead the company in this next research-intensive phase. Dr. Kawas` goal and passion is entrepreneurship that leads to disease modifying pharmaceuticals that address critical unmet medical needs.
Info Source
Press Release
Short Profile